1492 Capital Management’s Corcept Therapeutics CORT Stock Holding History

1492 Capital Management’s Portfolio CORT Stock Details CORT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-64,429	Closed	-$1.01M	–	95
2018 Q2	$1.01M	Sell	64,429 -75	-0.1%	-$1.3K	0.72%	46
2018 Q1	$1.06M	Sell	64,504 -5,328	-8%	-$98.7K	0.82%	40
2017 Q4	$1.26M	Sell	69,832 -202	-0.3%	-$3.66K	0.98%	33
2017 Q3	$1.35M	Buy	+70,034	New	+$1.04M	1.2%	28

Other funds holding CORT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

1492 Capital Management's CORT Position: Q3 2018 in Review

1492 Capital Management sold out of Corcept Therapeutics (CORT) in Q3 2018, closing a stake of 64,429 shares — an estimated $1.01M sold.

1492 Capital Management first reported a position in CORT in Q3 2017 and held it in 4 quarters. The position peaked at $1.35M in Q3 2017. 207 funds tracked by Wall St. Rank hold CORT as of Q3 2018.

1492 Capital Management reported no remaining Corcept Therapeutics position as of Q3 2018 after selling out during the quarter.
1492 Capital Management sold 64,429 Corcept Therapeutics shares in Q3 2018, an estimated $1.01M.
1492 Capital Management first reported a position in Corcept Therapeutics in Q3 2017 and held it in 4 quarters.
1492 Capital Management's Corcept Therapeutics position peaked at $1.35M in Q3 2017.
207 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q3 2018.

Based on 1492 Capital Management's 13F filing for Q3 2018, filed 14 Nov 2018.